FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 121 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Acing it: The ambitious early career researchers driving progress in cancer... January 21, 2022 2023 ASCO Annual Meeting Research Round Up: Advances in Treating Gynecologic... August 17, 2023 How a Simple Tool Is Saving Lives of Children with Cancer... February 15, 2024 Remembering With Gratitude January 7, 2021 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F) pCR Associated with Improved Survival Outcomes in Patients with Soft Tissue... Cancer Survivor with Strong Family History Was Denied Regular Screening Because... Time to meet our new chief scientist – Professor KJ Patel
